Lv2
190 积分 2022-06-07 加入
The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab
10天前
已完结
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study
1个月前
已完结
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
2个月前
已完结
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
2个月前
已完结
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials
2个月前
已完结
Management of Spinal Muscular Atrophy in the Adult Population
3个月前
已完结
Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study
3个月前
已完结
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
5个月前
已完结
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
5个月前
已完结
[Recommendations for the diagnosis and treatment of gout in China]
5个月前
已关闭
皖公网安备34019202002308
